3.18Open2.87Pre Close93 Volume166 Open Interest57.00Strike Price42.61KTurnover0.00%IV-0.77%PremiumNov 29, 2024Expiry Date4.06Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma11.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
lets gooooooo
No comment yet